维奈托克成功治疗一名患有严重慢性肾病的复发性慢性淋巴细胞白血病患者。
Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease.
作者信息
Sugiura Hiroyuki, Sezaki Nobuo, Ishikawa Tatsunori, Kuroi Taiga, Okamoto Sachiyo, Nomura Naho, Masunari Taro, Nakasako Yukio, Kiguchi Toru, Tanimoto Mitsune
机构信息
Department of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
Department of Diabetology and Nephrology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
出版信息
Clin Case Rep. 2022 Apr 14;10(4):e05735. doi: 10.1002/ccr3.5735. eCollection 2022 Apr.
Venetoclax is a promising new drug for relapsed or refractory chronic lymphocytic leukemia (CLL). However, venetoclax use had not been reported in severe chronic kidney disease (CKD) patients. We report the first case of relapsed CLL in a severe CKD patient that was successfully treated with venetoclax.
维奈托克是一种用于复发或难治性慢性淋巴细胞白血病（CLL）的有前景的新药。然而，严重慢性肾脏病（CKD）患者使用维奈托克的情况此前尚未见报道。我们报告了首例严重CKD患者复发CLL并成功接受维奈托克治疗的病例。
Zotero 插件